lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,146 rows where filing_year = 2023 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2954246 | STONINGTON GLOBAL da7482bf-a22f-45da-a22c-069b85f2b3b0 | Q1 | STONINGTON GLOBAL | 401105189 | SORRENTO THERAPEUTICS, INC. | 2023 | first_quarter | PHA | Promoting non-opioid pain management alternatives. | Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2023-03-27T11:04:21-04:00 | |
| 2954260 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING aea743c8-defe-4380-837f-2803c8dd186f | Q1 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023 | first_quarter | PHA | HR 1199, FIND Act, radiopharmaceutical reimbursement | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2023-03-27T18:31:23-04:00 | |
| 2954566 | PENN AVENUE PARTNERS edd30bec-25a3-47da-bca3-91f70905f320 | Q1 | PENN AVENUE PARTNERS | 400918672 | ALKERMES, INC. | 2023 | first_quarter | PHA | Regulatory and legislative issues impacting Alkermes. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-03T11:42:24-04:00 | |
| 2954637 | PENN AVENUE PARTNERS 0fad7689-1389-4f5c-a5c2-6f49ab6ea036 | Q1 | PENN AVENUE PARTNERS | 400918672 | UNITEDHEALTH GROUP, INC. | 2023 | first_quarter | PHA | Pharmacy benefit related issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 90000 | 0 | 0 | 2023-04-03T13:26:36-04:00 | |
| 2955051 | WATKINS & EAGER PLLC 672115f8-d2e2-48d6-94e4-a4aacb87926b | Q1 | WATKINS & EAGER PLLC | 401104403 | ZYNERBA PHARMACEUTICALS, INC. | 2023 | first_quarter | PHA | Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome. | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2023-04-05T11:19:18-04:00 | |
| 2955119 | AMERICAN COLLEGE OF CLINICAL PHARMACY fee4884b-f8ab-4153-b647-dc455ca8969f | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2023 | first_quarter | PHA | Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. | HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2023-04-05T13:39:08-04:00 | |
| 2955473 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 4f9b018f-59fb-48ae-a40c-4137c0d71781 | Q1 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 401103605 | PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION | 2023 | first_quarter | PHA | Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-06T12:45:53-04:00 | |
| 2955589 | REPUBLIC CONSULTING, LLC 5f565610-696f-4b2e-988f-4026cd1f26e9 | Q1 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2023 | first_quarter | PHA | Monitor Health Data Policy. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-06T15:41:57-04:00 | |
| 2955845 | INDEPENDENT PHARMACY COOPERATIVE f83017be-ac3e-480a-8432-c0a783306612 | Q1 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2023 | first_quarter | PHA | IPC supports S.127 Pharmacy Benefit Manager Transparency Act of 2023. IPC supports S.113 Prescription Pricing for the People Act of 2023. IPC supports H.R. 1770 Equitable Community Access to Pharmacists Services Act of 2023. IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC supports H.R. 1613 Drug Price Transparency in Medicaid Act of 2023. | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-04-07T13:12:41-04:00 | |
| 2956346 | LUNGREN LOPINA LLC f69f5935-5f04-4d76-9479-ac68f02e4584 | Q1 | LUNGREN LOPINA LLC | 401103314 | AMPAC FINE CHEMICALS | 2023 | first_quarter | PHA | Fair treatment for US based pharmaceutical ingredients | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-10T12:36:50-04:00 | |
| 2956605 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 54d7ebcb-1d3d-4208-af99-ba8c6b5e1360 | Q1 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 11003 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 2023 | first_quarter | PHA | CCAGW Urges Senate Judiciary Committee to Oppose S. 150 | SENATE | 310000 | 0 | 0 | 2023-04-10T15:46:12-04:00 | |
| 2956890 | MCDERMOTT+ LLC 391b453c-19cf-439a-9210-b728de831a4a | Q1 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2023 | first_quarter | PHA | Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-11T11:07:26-04:00 | |
| 2957069 | PANNONE LOPES DEVEREAUX & O'GARA LLC d563b0bd-3ac1-4ea5-b95e-2a91384c67c6 | Q1 | PANNONE LOPES DEVEREAUX & O'GARA LLC | 401105501 | AMGEN | 2023 | first_quarter | PHA | Prescription drug pricing. | 9000 | 0 | 0 | 2023-04-11T13:08:49-04:00 | ||
| 2957220 | UC HEALTH 88cf6ec4-1deb-4267-a973-94b7dec6b6af | Q1 | UC HEALTH | 401103195 | UC HEALTH | 2023 | first_quarter | PHA | 340B | HOUSE OF REPRESENTATIVES,SENATE | 37500 | 0 | 0 | 2023-04-11T15:09:16-04:00 | |
| 2957264 | RED+BLUE STRATEGIES a25220b8-283b-4f1c-99d6-5ea9eb4de71d | Q1 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2023 | first_quarter | PHA | S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2023-04-11T15:37:56-04:00 | |
| 2957571 | PARDES BIOSCIENCES, INC. 1a12c753-97e8-4a54-a861-d35307ae0862 | Q1 | PARDES BIOSCIENCES, INC. | 401106493 | PARDES BIOSCIENCES, INC. | 2023 | first_quarter | PHA | Physician prescribing of covid antivirals | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 120000 | 0 | 0 | 2023-04-12T10:25:50-04:00 | |
| 2957575 | PARDES BIOSCIENCES, INC. 7b178cfd-76ff-4ab0-bfa0-f3bee1a34931 | 2T | PARDES BIOSCIENCES, INC. | 401106493 | PARDES BIOSCIENCES, INC. | 2023 | second_quarter | PHA | Physician prescribing of covid antivirals | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 120000 | 0 | 1 | 2023-04-12T10:26:43-04:00 | |
| 2957599 | AMERICAN VETERINARY MEDICAL ASSOCIATION 3d3cb78b-2833-4844-a62f-b548d577d887 | Q1 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2023 | first_quarter | PHA | Compounding Guidance (GFI 256) H.R. 1418 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act | Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 330000 | 0 | 0 | 2023-04-12T10:49:30-04:00 | |
| 2957786 | HOLLAND & KNIGHT LLP 502f262d-1d08-42b5-a839-090dec11baa3 | Q1 | HOLLAND & KNIGHT LLP | 18466 | VIATRIS INC | 2023 | first_quarter | PHA | Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues, E-labeling; Inflation Reduction Act Implementation, Improving Generic Drug Access, PEPFAR. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-12T13:57:13-04:00 | |
| 2958423 | NELSON MULLINS RILEY & SCARBOROUGH 71611910-7a9e-47be-b7fb-aab9ebae4354 | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | TIDELANDS HEALTH | 2023 | first_quarter | PHA | Issues related to the 340B Drug Pricing Program | SENATE | 40000 | 0 | 0 | 2023-04-13T11:12:29-04:00 | |
| 2958566 | NELSON MULLINS RILEY & SCARBOROUGH f8687de3-c0f1-4610-8fa8-08486bfdc2d3 | Q1 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2023 | first_quarter | PHA | 340B Drug Pricing Program, patient co-pays legislation (H.R. 830) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-13T12:31:58-04:00 | |
| 2958568 | HOGAN LOVELLS US LLP 5e08d0d6-ba92-4667-891c-0c2ecedac04b | Q1 | HOGAN LOVELLS US LLP | 18422 | ALVOGEN, PHARMA US, INC. | 2023 | first_quarter | PHA | Issues related to COVID-19 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-04-13T12:33:37-04:00 | |
| 2958742 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 5e04a25c-271f-4a98-aea4-77b409b5eeca | 1A | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2023 | first_quarter | PHA | OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act -- not yet introduced. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 148265 | 0 | 0 | 2023-04-13T14:37:59-04:00 | |
| 2959033 | ARNOLD & PORTER KAYE SCHOLER LLP 1bb358dd-c662-4d25-b96b-e0e8c0aa926c | Q1 | ARNOLD & PORTER KAYE SCHOLER LLP | 4301 | PERRIGO COMPANY PLC | 2023 | first_quarter | PHA | Issues related to over-the-counter birth control. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-04-14T01:43:56-04:00 | |
| 2959078 | AARP 39aa04f7-e991-42f1-a3b9-beb034ed1208 | Q1 | AARP | 1694 | AARP | 2023 | first_quarter | PHA | S.79, Interagency Patent Coordination and Improvement Act of 2023. S.113, Prescription Pricing for the People Act of 2023. S.142, Preserve Access to Affordable Generics and Biosimilars Act of 2023. S.148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop (STALLING) Act. S.150, Affordable Prescriptions for Patients Act of 2023. S.935, the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act of 2023. No bill number. Discussed Medicare prescription drug inflation rebate program. No bill number. Discussed proposed Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. No bill number. Discussed proposed Contract Year 2024 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Program (Part D). H.R.485, Protecting Health Care for All Patients Act of 2023. No bill number. Discussed Drug-Price Transparency for Consumers (DTC) Act of 2023. No bill number. Discussed Biosimilar Red Tape Elimination Act. No bill number. Discussed Protecting Consumer Access to Generic Drugs Act. No bill number. Discussed federal prescription drug pricing. No bill number. Discussed insulin prices. No bill number. Discussed out of pocket cost smoothing in Part D. No bill number. Discussed prescription drug access and prices. | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 3850000 | 0 | 0 | 2023-04-14T08:31:06-04:00 | |
| 2959207 | KOUNTOUPES DENHAM CARR & REID, LLC 16b02461-d413-4a83-ad3e-58c6677f4e2c | 1T | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2023 | first_quarter | PHA | Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing and supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2023-04-14T09:56:34-04:00 | |
| 2959267 | DAVE KOLBE CONSULTING 9f87c7ae-eaa1-4970-9324-8baee32e8d00 | Q1 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2023 | first_quarter | PHA | S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation. | SENATE | 30000 | 0 | 0 | 2023-04-14T10:27:32-04:00 | |
| 2959397 | ALB SOLUTIONS a951fe7d-a3bc-465f-893b-82bbbb1b7a51 | Q1 | ALB SOLUTIONS | 401105973 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2023 | first_quarter | PHA | Issues related to regulatory and legislative developments regarding biosimilars. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-14T12:12:15-04:00 | |
| 2960627 | BROYDRICK & ASSOCIATES 47526e90-2fbe-47fe-b58b-4e50f0dec912 | Q1 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2023 | first_quarter | PHA | Funding for drug treatment for PTSD and COVID-19, BARDA appropriations. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-17T09:48:20-04:00 | |
| 2960755 | LINCOLN PARK GROUP L.L.C. b8c87ae2-8ed9-4f2c-8467-c41775cc7611 | Q1 | LINCOLN PARK GROUP L.L.C. | 401104374 | CANADIAN INTERNATIONAL PHARMACY ASSOCIATION | 2023 | first_quarter | PHA | Issues related to importation of medicines for personal use. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-17T10:24:19-04:00 | |
| 2960861 | THE CONSILIO GROUP d24787c8-ca30-48d3-a80f-0491ca1a5b97 | Q1 | THE CONSILIO GROUP | 400374717 | PARATEK PHARMACEUTICALS | 2023 | first_quarter | PHA | Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use | Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office | 36000 | 0 | 0 | 2023-04-17T10:50:49-04:00 | |
| 2961049 | EMERGENT STRATEGIES 0edef954-e4af-4d10-b6bf-1c20fc14129f | Q1 | EMERGENT STRATEGIES | 401104778 | GENBIOPRO, INC. | 2023 | first_quarter | PHA | FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2023-04-17T11:17:03-04:00 | |
| 2961219 | FORBES-TATE 1fff84e1-8e6f-4804-b36a-40759a34f5fa | Q1 | FORBES-TATE | 400976792 | INDEPENDENT PHARMACY COOPERATIVE | 2023 | first_quarter | PHA | Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-17T11:48:28-04:00 | |
| 2961259 | FORBES-TATE ba81b86f-1295-41e4-a223-e0db04fda87c | Q1 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2023 | first_quarter | PHA | Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-17T11:54:08-04:00 | |
| 2961456 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 2870aac4-a7f1-485b-96ff-2bea3c9380e6 | Q1 | KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) | 401105192 | CVS HEALTH | 2023 | first_quarter | PHA | Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-17T12:27:24-04:00 | |
| 2962431 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION d78af6fd-213f-4209-9cb3-b1413faf9609 | Q1 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 27478 | NATIONAL COMMUNITY PHARMACISTS ASSOCIATION | 2023 | first_quarter | PHA | H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; Draft legislation, Drug Shortage Protection Act; | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 370000 | 0 | 0 | 2023-04-17T16:21:23-04:00 | |
| 2962763 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 339b49eb-dcb0-48a4-a796-68369753d0c4 | Q1 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | WALGREEN CO. | 2023 | first_quarter | PHA | Pharmacist provider status Pharmacy benefits on military bases Issues related to drug pricing Issues related to COVID-19 relief Inflation Reduction Act of 2022 INFORM Act Issues related to access and distribution of pharmaceutical products | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-17T17:48:31-04:00 | |
| 2962802 | GOVERNMENT COUNSEL, LLC 99b60aba-9bfc-4737-bdc1-717baefad4bc | Q1 | GOVERNMENT COUNSEL, LLC | 401105070 | HEALTHCARE DISTRIBUTION ALLIANCE | 2023 | first_quarter | PHA | H.R. 501-Block, Report, And Suspend Suspicious Shipments Act; General issues relating access to medication assisted treatment. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 60000 | 0 | 0 | 2023-04-17T18:06:02-04:00 | |
| 2962971 | CAPITOL COUNSEL LLC 31fd640c-ddbc-4843-ae02-52d606aaadc8 | Q1 | CAPITOL COUNSEL LLC | 313715 | EMD SERONO, INC. | 2023 | first_quarter | PHA | Issues regarding the availability and pricing of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-17T21:25:23-04:00 | |
| 2963005 | CAPITOL COUNSEL LLC 2a92e498-9669-4864-a76e-2c13b1132569 | Q1 | CAPITOL COUNSEL LLC | 313715 | VERTEX PHARMACEUTICALS INCORPORATED | 2023 | first_quarter | PHA | Monitoring and advocacy on matters related to the pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-17T22:15:08-04:00 | |
| 2963151 | ELI LILLY AND COMPANY fb33fc1e-5626-4c68-8a2d-09eb09e49b51 | Q1 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2023 | first_quarter | PHA | Hospital discounts; 340B program | HOUSE OF REPRESENTATIVES,SENATE | 1470000 | 0 | 0 | 2023-04-18T07:57:48-04:00 | |
| 2963226 | ASSOCIATION FOR ACCESSIBLE MEDICINES e3e3c44f-ada4-4240-bc15-eb44d4d0ff40 | Q1 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 16032 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2023 | first_quarter | PHA | Prescription Drug Costs. Drug Pricing. Pre-Hatch-Waxman ANDAs (PANDAs). Civil Monetary Penalties. Pharmaceutical Exclusivity. 180-Day Exclusivity. Labeling of Generic Drugs and Biosimilars. Section 505(j)(10) Labeling [Legislation not yet introduced]. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. Generic Formulations. Incentivize Domestic Manufacturing. Drug Shortages. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. Hybrid Biosimilar Applications [Legislation not yet introduced]. 505(b)(2) Biosimilar Proposal. Same Strength Requirement for Biosimilars. FDA Inspections. Energy & Commerce Factory Inspection Legislation. FDA-PTO Collaboration. FDA Genus Decision. FDA Catalyst Decision. Shaheen-Cassidy Citizen Petition Legislation. 506I Marketing Status Updates. Buy American Proposals. Issues Related to COVID-19. Inflation Reduction Act (IRA) Implementation. | Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE | 480000 | 0 | 0 | 2023-04-18T08:48:45-04:00 | |
| 2963487 | RICCHETTI INCORPORATED b9eff7aa-04c5-4699-8b0f-793bf4e57a75 | Q1 | RICCHETTI INCORPORATED | 62778 | EISAI, INC. | 2023 | first_quarter | PHA | Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-04-18T10:19:36-04:00 | |
| 2963517 | RICCHETTI INCORPORATED 29dba94a-855b-47d4-99f2-1c11c453d64a | Q1 | RICCHETTI INCORPORATED | 62778 | HORIZON THERAPEUTICS USA INC | 2023 | first_quarter | PHA | Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-04-18T10:23:36-04:00 | |
| 2963532 | RICCHETTI INCORPORATED 520f85e7-0e9c-41da-a4db-2b86fa9192c3 | Q1 | RICCHETTI INCORPORATED | 62778 | IPSEN BIOPHARMACEUTICALS, INC. | 2023 | first_quarter | PHA | Issues related to pharmaceutical industry, generally ssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-18T10:25:42-04:00 | |
| 2963534 | BUCHANAN INGERSOLL & ROONEY PC 371b1e73-db42-4437-ad94-a6fa9be6714a | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | AIM IMMUNOTECH INC. | 2023 | first_quarter | PHA | Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 20000 | 0 | 0 | 2023-04-18T10:26:02-04:00 | |
| 2963538 | RICCHETTI INCORPORATED e343a154-9175-4cf7-ba89-450a74efb825 | Q1 | RICCHETTI INCORPORATED | 62778 | NEUROCRINE BIOSCIENCES, INC. | 2023 | first_quarter | PHA | Issues related to pharmaceutical industry, generally | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-18T10:26:33-04:00 | |
| 2963734 | CARD & ASSOCIATES, LLC b47e4680-61fb-4c3e-9849-0bbeb4b64ae3 | Q1 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2023 | first_quarter | PHA | Monitor legislation and on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-18T11:06:19-04:00 | |
| 2963741 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH bd2881bd-9b4d-4a2b-80cf-51e4d8f33b56 | Q1 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 401104060 | THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 2023 | first_quarter | PHA | S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-18T11:06:40-04:00 | |
| 2963968 | CAPITOL COUNSEL LLC 7a784a19-26c8-468e-a425-39951d60fd54 | Q1 | CAPITOL COUNSEL LLC | 313715 | PHARMAPOTHECA A, INC. | 2023 | first_quarter | PHA | Advocacy to encourage FDA to establish science-based limits to control contamination of a potential genotoxic trace impurity in amphetamine-based ADHD dosage forms. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-18T11:45:29-04:00 | |
| 2964172 | BROWN & FORTUNATO, P.C. 94d9ad75-b7eb-4a09-9d0a-e65e9a8e8731 | Q1 | BROWN & FORTUNATO, P.C. | 401104878 | PROMPTCARE COMPANIES, INC. | 2023 | first_quarter | PHA | Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. | Centers For Medicare and Medicaid Services (CMS) | 10000 | 0 | 0 | 2023-04-18T12:22:07-04:00 | |
| 2964509 | KOUNTOUPES DENHAM CARR & REID, LLC c5ac2294-a044-4967-bc54-4205d86de63e | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ABBOTT LABORATORIES | 2023 | first_quarter | PHA | Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 7213, the Equitable Community Access to Pharmacist Services Act. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-18T13:42:33-04:00 | |
| 2965115 | RED+BLUE STRATEGIES 07411d40-fd38-4029-92fa-f64151c76e28 | Q1 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2023 | first_quarter | PHA | Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-18T15:43:33-04:00 | |
| 2965430 | ARENTFOX SCHIFF LLP 17998653-6abb-4e0f-ab16-a02ca920870c | Q1 | ARENTFOX SCHIFF LLP | 4208 | AMERICAN PHARMACY COOPERATIVE, INC. | 2023 | first_quarter | PHA | Prescription drug pricing generally | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2023-04-18T16:25:20-04:00 | |
| 2965652 | TWENTY-FIRST CENTURY GROUP, INC. a6f5e3fb-77d9-4b8c-9131-5705cf484f47 | Q1 | TWENTY-FIRST CENTURY GROUP, INC. | 38687 | CARDINAL HEALTH, INC. | 2023 | first_quarter | PHA | Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 0 | 2023-04-18T16:57:01-04:00 | |
| 2966026 | BROWNSTEIN HYATT FARBER SCHRECK, LLP eb78f14a-be56-4bb7-bb99-035a8da80ff8 | Q1 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | ROMARK GLOBAL PHARMA, LLC | 2023 | first_quarter | PHA | Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics' | HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2023-04-18T18:22:52-04:00 | |
| 2966509 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 7ceaa7ae-a5bb-4bb9-8467-5360445cf655 | Q1 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | LILLY USA, LLC | 2023 | first_quarter | PHA | Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-18T23:45:22-04:00 | |
| 2966705 | BOLD STRATEGIES, LLC 3a91200a-4de7-4067-b02d-edcad823b626 | Q1 | BOLD STRATEGIES, LLC | 401104653 | MORRIS & DICKSON CO., LLC | 2023 | first_quarter | PHA | Prescription drug issues generally. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-04-19T08:37:52-04:00 | |
| 2966706 | KOUNTOUPES DENHAM CARR & REID, LLC 2bf04802-8d80-4700-a786-b46aeaa35c36 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2023 | first_quarter | PHA | General issues related to over-the-counter pharmaceutical supply chain. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-19T08:38:54-04:00 | |
| 2966749 | KOUNTOUPES DENHAM CARR & REID, LLC 33a58608-9352-46d6-a44f-91db22ad4c48 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2023 | first_quarter | PHA | Issues related to pharmacies including legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-04-19T08:53:17-04:00 | |
| 2966869 | FAEGRE DRINKER BIDDLE & REATH LLP 5c97e429-f753-4619-a243-7df6c849cf57 | Q1 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) | 2023 | first_quarter | PHA | Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-04-19T09:22:33-04:00 | |
| 2966874 | FAEGRE DRINKER BIDDLE & REATH LLP a5b28ebe-10d2-4a22-97a7-dfbc39184bf4 | Q1 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | EMPOWER PHARMACY | 2023 | first_quarter | PHA | Issues related to compounding medications, including safety and supply chain issues. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-04-19T09:23:02-04:00 | |
| 2967102 | MEHLMAN CONSULTING, INC. 429558b6-a989-4735-adbc-16d6f2738280 | Q1 | MEHLMAN CONSULTING, INC. | 284950 | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | 2023 | first_quarter | PHA | Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-19T09:54:17-04:00 | |
| 2967188 | NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 5f028448-d8bf-4639-abdd-ddb32b39ff41 | Q1 | NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) | 28264 | NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) | 2023 | first_quarter | PHA | Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Inflation Reduction Act Implementation. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-19T10:03:03-04:00 | |
| 2967220 | UNIVERSITY OF IOWA 8a403bd0-f390-4027-bc89-1e9be69000d5 | Q1 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2023 | first_quarter | PHA | N/A | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-19T10:06:02-04:00 | |
| 2967481 | SQUIRE PATTON BOGGS 5b856e63-a6db-49cf-957c-4cfb8d982d7e | Q1 | SQUIRE PATTON BOGGS | 30906 | SK HYNIX AMERICA, INC. | 2023 | first_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 200000 | 0 | 0 | 2023-04-19T10:28:28-04:00 | |
| 2967682 | VAN SCOYOC ASSOCIATES d9007232-9b4f-4865-97ac-8a18b3a31e8c | Q1 | VAN SCOYOC ASSOCIATES | 39837 | ZEBRA TECHNOLOGIES CORP. | 2023 | first_quarter | PHA | National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology | HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2023-04-19T10:43:02-04:00 | |
| 2967748 | FAEGRE DRINKER BIDDLE & REATH LLP 6320b445-2a39-43c4-bcf8-67a0fa9b9dd8 | Q1 | FAEGRE DRINKER BIDDLE & REATH LLP | 12631 | NATIONAL ASSOCIATION OF BOARDS OF PHARMACY | 2023 | first_quarter | PHA | Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth. | Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 30000 | 0 | 0 | 2023-04-19T10:48:25-04:00 | |
| 2967976 | FORBES-TATE b7e1b4ac-68ce-4ac9-ac9b-8c280333921c | Q1 | FORBES-TATE | 400976792 | PHRMA | 2023 | first_quarter | PHA | Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-04-19T11:02:59-04:00 | |
| 2968284 | BURRELL INTERNATIONAL GROUP LLC 7ad9f799-4645-49e8-a690-b76ec301294c | Q1 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | ACER THERAPEUTICS | 2023 | first_quarter | PHA | COVID-19 therapeutics and Medical Countermeasures, Rare Disease, and Re-purposed drugs; Defense Appropriations for MCM Development | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-19T11:30:07-04:00 | |
| 2968442 | BLUECROSS BLUESHIELD OF TENNESSEE 189d194b-0d11-4792-8916-7ab92a47cd6c | Q1 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2023 | first_quarter | PHA | Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. | HOUSE OF REPRESENTATIVES,SENATE | 195000 | 0 | 0 | 2023-04-19T11:41:53-04:00 | |
| 2968461 | BURRELL INTERNATIONAL GROUP LLC 5c7712e7-fce9-4275-b0c7-f24641643fa3 | Q1 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | TONIX PHARMACEUTICALS HOLDING CORP. | 2023 | first_quarter | PHA | LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-19T11:43:02-04:00 | |
| 2968479 | WINNING STRATEGIES WASHINGTON e1997dae-0a51-4a50-aa33-e44336fb5a2d | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | HEALTHCARE INSTITUTE OF NEW JERSEY | 2023 | first_quarter | PHA | Legislation related to extension of FDA user fees | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2023-04-19T11:44:57-04:00 | |
| 2968503 | BURRELL INTERNATIONAL GROUP LLC d6b18087-1dc2-4601-818e-761dd1670880 | Q1 | BURRELL INTERNATIONAL GROUP LLC | 401103483 | SHIONOGI INC. | 2023 | first_quarter | PHA | Pandemic preparedness; Antimicrobial resistance; Draft of proposed PASTEUR Act language (No bill numbers yet) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-19T11:48:59-04:00 | |
| 2968765 | KOUNTOUPES DENHAM CARR & REID, LLC 017a58c5-e077-471e-bb83-a8ca93cd2be7 | Q1 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2023 | first_quarter | PHA | Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T12:15:42-04:00 | |
| 2969155 | WINNING STRATEGIES WASHINGTON c1ce83a0-27ad-4743-b01c-9943e0cbad33 | Q1 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2023 | first_quarter | PHA | Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2023-04-19T13:01:45-04:00 | |
| 2969641 | CROSSROADS STRATEGIES, LLC d06c502c-14a7-47cc-a8d4-af5560b52f70 | Q1 | CROSSROADS STRATEGIES, LLC | 400531586 | INDIVIOR INC. | 2023 | first_quarter | PHA | Issues related to overdose reversal products; H.R.2617, Consolidated Appropriations Act, 2023 (P.L.117-328) implementation; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2023-04-19T13:46:11-04:00 | |
| 2969907 | SHIONOGI INC. c526e3c1-dccf-4e75-8519-f67586955af2 | Q1 | SHIONOGI INC. | 401107081 | SHIONOGI INC. | 2023 | first_quarter | PHA | Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 130000 | 0 | 0 | 2023-04-19T14:11:36-04:00 | |
| 2970001 | PORT SIDE STRATEGIES, LLC 144b5ed1-eb37-42d1-8a87-7bc80aa4b653 | Q1 | PORT SIDE STRATEGIES, LLC | 401105394 | NEW VENTURE FUND | 2023 | first_quarter | PHA | Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-04-19T14:17:25-04:00 | ||
| 2970028 | FAMILIES USA FOUNDATION, INC. 0980ede3-1969-406d-a5c3-2e085c101934 | Q1 | FAMILIES USA FOUNDATION, INC. | 14108 | FAMILIES USA FOUNDATION INC | 2023 | first_quarter | PHA | S.113Prescription Pricing for the People Act of 2023To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. s.150Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2023-04-19T14:19:01-04:00 | ||
| 2970113 | CORNERSTONE GOVERNMENT AFFAIRS, INC. b8acb6c6-136b-48ee-929c-8a46b6ddab48 | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2023 | first_quarter | PHA | Health-related issues including reimbursement, research, public-health & clinical care. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2023-04-19T14:24:36-04:00 | |
| 2970161 | PRIME POLICY GROUP f3d4baca-93bf-47fc-ac98-da4ced23d415 | Q1 | PRIME POLICY GROUP | 400532589 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2023 | first_quarter | PHA | H.R. 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 60000 | 0 | 0 | 2023-04-19T14:27:45-04:00 | |
| 2970257 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS e014a05c-e9d8-497e-a6a1-1fc1d1907005 | Q1 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2023 | first_quarter | PHA | Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to COVID-19 response recommendations (generally, no specific legislation). The Protect 340B Act (H.R. 2534), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to the rollout of Test to Treat Programs (generally, no specific legislation). Issues related to pharmacy residency funding (generally, no specific legislation). | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 220000 | 0 | 0 | 2023-04-19T14:35:03-04:00 | |
| 2970860 | E3 STRATEGIC CONSULTING GROUP c593a642-9c9d-45a2-927b-fe2a4bdee017 | 1T | E3 STRATEGIC CONSULTING GROUP | 401104104 | HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) | 2023 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 1 | 2023-04-19T15:26:11-04:00 | ||
| 2970882 | E3 STRATEGIC CONSULTING GROUP b7e1d6d7-8737-4723-853e-df0e19a61c76 | Q1 | E3 STRATEGIC CONSULTING GROUP | 401104104 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2023 | first_quarter | PHA | Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023 | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2023-04-19T15:28:12-04:00 | |
| 2971112 | POLARIS GOVERNMENT RELATIONS, LLC a96146b5-4c5c-400f-b760-85902ae6c44d | Q1 | POLARIS GOVERNMENT RELATIONS, LLC | 307730 | CIGNA CORPORATION | 2023 | first_quarter | PHA | Drug pricing and issues facing the pharmacy benefit manager industry generally | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2023-04-19T15:43:45-04:00 | |
| 2971312 | AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 7c9e503f-23bd-4eab-af01-4af7b918c865 | Q1 | AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES | 2321 | AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES | 2023 | first_quarter | PHA | S 1139- Lowering the Price of Prescription Drugs | HOUSE OF REPRESENTATIVES,SENATE | 490000 | 0 | 0 | 2023-04-19T15:53:36-04:00 | |
| 2972368 | HEALTHSPERIEN 6d2a1eb8-c5d9-44ac-9965-967ce0e21a48 | Q1 | HEALTHSPERIEN | 401103150 | EXACT CARE PHARMACY | 2023 | first_quarter | PHA | Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-19T17:21:16-04:00 | |
| 2972820 | INVARIANT LLC 26fe8d4b-47d0-4962-b412-c17181a02745 | Q1 | INVARIANT LLC | 314237 | SK HYNIX AMERICA INC. | 2023 | first_quarter | PHA | Monitor proposals and issues related to biopharmaceuticals. | Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2023-04-19T18:07:24-04:00 | |
| 2973062 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 4c05cc3e-3f31-416e-bfa7-ef51e4964bd2 | Q1 | BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. | 323876 | BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 2023 | first_quarter | PHA | INSULIN Act; Insulin Out of Pocket Charges; S. 148 - Stop STALLING Act Sponsor: Sen. Amy Klobuchar (D-MN) S. 142 - Preserve Access to Affordable Generics and Biosimilars Act Sponsor: Sen. Amy Klobuchar (D-MN) S. 150 - Affordable Prescriptions for Patients Act of 2023 Sponsor: Sen. John Comyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of2023 Sponsor: Sen. Maria Cantwell (D-WA) S. 954 - Affordable Insulin Now Act of 2023 Sponsor: Sen. Raphael Warnock (D-GA) | Centers For Medicare and Medicaid Services (CMS),SENATE | 0 | 0 | 2023-04-19T18:40:24-04:00 | ||
| 2973144 | KING & SPALDING LLP c0715f23-abe0-41bc-8a6d-7442a52960c8 | Q1 | KING & SPALDING LLP | 21632 | SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) | 2023 | first_quarter | PHA | Advocacy on low income subsidy benefits | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T18:59:21-04:00 | |
| 2973199 | TARPLIN, DOWNS & YOUNG, LLC 69a07c2c-8470-4eef-b6fb-7f8e1c083995 | Q1 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | ASTRAZENECA | 2023 | first_quarter | PHA | IRA implementation, drug coverage and reimbursement, drug shortages, supply chain integrity, innovation, transparency, 340B | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2023-04-19T19:18:26-04:00 | |
| 2973210 | DESIMONE CONSULTING, LLC b0fb6e75-fa88-4873-ab20-892c27012708 | Q1 | DESIMONE CONSULTING, LLC | 400931695 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2023 | first_quarter | PHA | Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-19T19:20:47-04:00 | |
| 2973492 | MARSHALL & POPP, LLC 2a123ed9-82f0-4077-8a9e-d314107e6d31 | Q1 | MARSHALL & POPP, LLC | 401105121 | AMGEN USA INC. | 2023 | first_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T20:41:16-04:00 | |
| 2973671 | MARSHALL & POPP, LLC d017204a-7fd0-402f-bd5f-ed10dc959cfb | Q1 | MARSHALL & POPP, LLC | 401105121 | GENENTECH, INC. | 2023 | first_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to 340B. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T21:25:25-04:00 | |
| 2973704 | WEST FRONT STRATEGIES LLC 11880880-cc49-4ab0-88ca-dcdfd2b6b8fe | Q1 | WEST FRONT STRATEGIES LLC | 401103493 | FRESENIUS KABI USA LLC | 2023 | first_quarter | PHA | Issues related to drug pricing; issues related to Biosimilars; issues related to competition. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-19T21:29:55-04:00 | |
| 2973709 | MARSHALL & POPP, LLC 14d37ae9-f9c5-4c49-86d2-792c3bee7295 | Q1 | MARSHALL & POPP, LLC | 401105121 | PFIZER, INC. | 2023 | first_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to 340B. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T21:30:44-04:00 | |
| 2973713 | MARSHALL & POPP, LLC d5c4910e-ad30-4d6d-91d9-5d609a3d100f | Q1 | MARSHALL & POPP, LLC | 401105121 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2023 | first_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to 340B. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2023-04-19T21:31:45-04:00 | |
| 2973720 | MARSHALL & POPP, LLC dfa09439-7e39-4b53-a490-d50e6d479018 | Q1 | MARSHALL & POPP, LLC | 401105121 | SANOFI U.S. SERVICES, INC. | 2023 | first_quarter | PHA | Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to 340B. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2023-04-19T21:32:51-04:00 | |
| 2973812 | WEST FRONT STRATEGIES LLC 88ceccf7-4da2-4457-99fd-b459f8c46d1c | Q1 | WEST FRONT STRATEGIES LLC | 401103493 | VIATRIS INC | 2023 | first_quarter | PHA | Issues related to e-labeling; monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2023-04-19T22:01:05-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);